AARS Hot Topics

Dr. Andrea Zaenglein was recognized at the 17th Annual AARS Networking Reception in San Diego last month, as she concluded her term as AARS President. Incoming President Dr. Jim Del Rosso. Other new officers and Directors have been announced. AARS leadership past and present was well represented from the podium at the Annual Meeting of the American Academy of Dermatology (AAD) in San Diego in March. Among those presenting was Valerie Callender, MD, whose session “Lasers and Energy Devices in the Treatment of Acne” were spotlighted in Derm World Meeting News. Learn about some of the latest important research in acne, rosacea, and HS while interacting with some of the brightest young minds in the field and AARS leadership on Wednesday, May 15, 2024 from 11:00 AM –1:00 PM at the 11th Annual AARS Scientific Symposium at the 81st Annual Meeting of the Society for Investigative Dermatology at the Hilton Anatole in Dallas, Texas. Chaired by Dr. Lawrence Eichenfield. The AARS mission is to promote, support, develop and provide an educational forum for the exchange of information related to acne/HS and rosacea and to fund clinical research opportunities for dermatology professionals who strive to improve the care of patients who suffer from acne and rosacea. The deadline to submit applications is Friday, May 31, 2024.

The American Acne and Rosacea Society (AARS) is the only professional society focused on acne, hidradenitis suppurativa, and rosacea. Support AARS by becoming a member!

New research offers new insights on the use of cannabis among patients with hidradenitis suppurativa. The findings don't surprise Adam Friedman, MD, Professor and Chair of Dermatology and Director of the HS program at GW School of Medicine and Health Sciences. He shares his insights on the paper, published in the Journal of Cutaneous Medicine and Surgery, and offers tips for counseling and managing patients. Dr. Friedman is a Director of the American Acne and Rosacea Society.

The American Acne and Rosacea Society (AARS) is the only professional society focused on acne, hidradenitis suppurativa, and rosacea. Support AARS by becoming a member!

In a new AARS video dermatologist Andrea Zaenglein, MD, FAAD and OB/Gyn Sarah K. Horvath, MD, MSHP, FACOG discuss patient counseling and recommendations for prescribing emergency contraception for patients on isotretinoin. Crown Laboratories, which owns the PanOxyl line of acne care products, plans to acquire Revance Therapeutics. New data for izokibep, a novel IL-17A inhibitor, for HS, and more.

The American Acne and Rosacea Society (AARS) is the only professional society focused on acne, hidradenitis suppurativa, and rosacea. Support AARS by becoming a member!

With a recent publication assessing the frequency of lab monitoring for patients with acne being treated with isotretinoin, AARS President Elect Jonathan Weiss, MD, FAAD, weighs in on the latest expert thinking. He also compares the current publication to the Guidelines of Care for Acne from the American Academy of Dermatology.

The American Acne and Rosacea Society (AARS) is the only professional society focused on acne, hidradenitis suppurativa, and rosacea. Support AARS by becoming a member!

Approved late last year to treat HS, bimekizumab was the subject of several publications in 2024, including phase 3 pivotal trial data. AARS President James Q. Del Rosso, DO gives an update on key data considerations. You can watch Dr. Del Rosso's full discussion of trial design, efficacy data, and safety findings online at acneandrosacea.org.

The American Acne and Rosacea Society (AARS) is the only professional society focused on acne, hidradenitis suppurativa, and rosacea. Support AARS by becoming a member!